Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepNet Acute HCV-V study of 8 weeks of sofosbuvir + velpatasvir for acute hepatitis C
2018-003474-27Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and velpatasvir in hepatitis C virus infection, sponsored by Hannover Medical School. Primary endpoint: Sustained virologic response at 12 weeks after treatment. Started Jan 2019; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2018-003474-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003474-27.